KR920703114A - 접합체 백신을 위한 시토킨 및 호르몬 운반체 - Google Patents

접합체 백신을 위한 시토킨 및 호르몬 운반체

Info

Publication number
KR920703114A
KR920703114A KR1019920700087A KR920700087A KR920703114A KR 920703114 A KR920703114 A KR 920703114A KR 1019920700087 A KR1019920700087 A KR 1019920700087A KR 920700087 A KR920700087 A KR 920700087A KR 920703114 A KR920703114 A KR 920703114A
Authority
KR
South Korea
Prior art keywords
antigen
vaccine composition
oligomer
polymer
conjugate
Prior art date
Application number
KR1019920700087A
Other languages
English (en)
Inventor
필라이 슈브라므니아
에비 로날드
Original Assignee
원본미기재
프락시스 바이오로직스 인코포레이팃드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 프락시스 바이오로직스 인코포레이팃드 filed Critical 원본미기재
Publication of KR920703114A publication Critical patent/KR920703114A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

내용 없음

Description

접합체 백신을 위한 시토킨 및 호르몬 운반체
[도면의 간단한 설명]
제1도는 조(粗) 폴리리보실리비톨포스페이트(PRP)-rhIL-2 접합체에 비교한 접합안된 제조합 사람 IL-2(rhIL-2)의 고압 액체 크로마토그래피(HPLC)분석을 나타낸다.
제2도는 출발 반응에서 PRP 대 rhIL-2 2:1(w/w) 비율의 PRP-rhIL-2 접합체의 크로마토그램을 나타낸다.
제3도는 rhIL-2 모의 접합체의 크로마토그램을 나타내며, 접합방법을 첨가된 PRP없이 수행하였다. 제4도는 PRP에 대한 모노클로날 항체로 검출된, 선택된 접합체의 임뮤노노블롯을 나타낸다. 좌측에서 우측으로, 레인은 PRP-CRM, rhIL-2, PRP, PRP-rhIL-2(2X), PRP-rhIL-2(2X), 블랭크, PRP-rhIL-20X), 및 PRP-rhIL-2(20X)을 갖는다.
제5a-c도는 (a) 접합안된 제조합소의 IL-2(BrIL-2), (b) PRP-BrIL-2(2:1)접합체 및 (c) PRP-BrIL-2(20:1)접합체의 RPLC 분석을 나타낸다.
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (55)

  1. 수용체가 면역시스템의 세포상에서 발현되고, 면역조절 활성을 갖는 시토킨, 림포킨, 호르몬, 성장인자 또는 이의 일부에 결합된, 보통은 시토킨. 림모킨, 호르몬 또는 성장 인자와 결합되지 않는 항원으로 구성되는 면역원성 접합체.
  2. 제1항에 있어서, 시트킨 또는 림포킨은 인더페론, 인터루킨 -1α, 인티루킨 -β, 인티루킨-2 또는 이의 일부인 접합체.
  3. 제1항에 있어서, 호르몬 또는 성장인자는 종양괴사인자, 프롤락턴, 표피성장인자, 조직성장인자, 과립구대식세포 집락 자극인자, 과립구 집락 자극인자, 인슐린 유사 성장인자, 소마트트로핀 또는 인슐린인 접합체.
  4. 제1항에 있어서, 항원은 시트킨 또는 호르몬에 공유결합되는 접합체.
  5. 제4항에 있어서, 항원은 시토킨, 립포킨, 호르몬 또는 성장인자에 환원성 아민화에 의해서 결합되는 접합체.
  6. 제1항에 있어서, 항원은 시토킨, 림포킨, 호르몬 또는 성장인자에 유진자 융합기술에 의해 결합되는 접합체.
  7. 제1항에 있어서, 항원은 온혈동물 또는 사람 병원체의 비루스, 세균, 진균 또는 기생생물 항원인 접합체.
  8. 제1항에 있어서, 항원은 탄수화물 함유 항원인 접합체.
  9. 제8항에 있어서, 탄수화물 함유 항원은 올리고당류 또는 다당류인 접합체.
  10. 제1항에 있어서, 항원은 세균 협막 중합체, 올리고머 또는 이의 단편인 접합체.
  11. 제10항에 있어서, 중합체 또는 올리고머는 헤모필루스 인플루엔자, 에쉐리시아 콜리, 네이세리아 메닝기티디스, 스트렙토코쿠스 뉴모니아, 스트렙트코쿠스피오게네스, 브란하멜라카타르할리스, 비브리오 콜레라, 코리네박테리아디프테리아, 네이세리아고노르흐에아, 보르데델라 퍼루스시스, 슈도모나스 아에 루기 노사, 스타필로코쿠스 아우레우스, 클렙시엘라 뉴모니아 또는 콜로스트리듐 테타니로부터 유래된 접합체.
  12. 제11항에 있어서, 중합체 또는 올리고머는 폴리리보실리비를 포스페이트인 집합체.
  13. 제11항에 있어서, 중합체 또는 올리고머는 스트렙트코쿠스 뉴모니아로 부터 유래된 접합체.
  14. 제13항에 있어서, 중합체 또는 올리고머는 에스. 뉴모니아의 혈청형 1, 4, 5, 6A, 6B, 9V, 14, 18C, 19F 또는 23F로 부터 유래된 집합체.
  15. 제10항에 있어서, 중합체 또는 올리고머는 엔. 메닝기티디스의 그룹 A 또는 그룹 C협막당으로부터 유래된 접합체.
  16. 제1항에 있어서, 항원은 세균의 세포벽 펩티도글리칸 또는 이의 단편인 접합체.
  17. 제1항에 있어서, 항원은 세균의 지방다당류 또는 이의 성분인 접합체.
  18. 제약학적으로 허용가능한 담체 및 임의의 보조제내에, 수용체가 면역시스템의 세포상에서 발현되고, 면역조절활성을 갖는 시트킨, 림포킨, 호르몬, 성장인자 또는 이의 일부에 결합된, 보통은 시트킨, 림포킨, 호르몬 또는 성장인자와 결합되지 않는 항원으로 구성되는 면역원성 접합체를 포함하는 백신 조성물.
  19. 제18항에 있어서, 시트킨 또는 림포킨이 인터페론, 인티루킨 -1α, 인터루킨 -1β, 인터루킨 -2 또는 이의 일부인 백신 조성물.
  20. 제18항에 있어서, 호르몬 또는 성장인자가 종양피사인자, 프롤락틴, 표피성장인자, 조직성장인자, 과립구 거대세포 집락 자극인자, 과립구 집락 자극인자, 인슐린 유사 성장인자, 소마토트로핀 또는 인슐린인 백신조성물.
  21. 제18항에 있어서, 항원은 온혈동물 또는 사람 병원체의 세균, 진균, 기생생물 항원인 백신 조성물.
  22. 제18항에 있어서, 항원은 탄수화물 함유 항원인 백신 조성물.
  23. 제22항에 있어서, 항원은 올리고망류 또는 다당류인 백신 조성물.
  24. 제23항에 있어서, 항원은 세균 협막 중합체, 올리고머 또는 이의 단편인 백신 조성물.
  25. 제24항에 있어서, 중합게 또는 올리고머는 헤모필루스 인플루엔자, 에쉐리시아 클리, 네이세리아 메닝기티디스, 스트렙트코쿠스뉴모니아, 스트렙트코쿠스피오케네스, 브란하멜라 카타르할리스, 비브리오 콜레라, 코리 네박테리아디프테리아, 네이세리아 고노르호에아, 브르데탤라 퍼투스시스, 슈도모나스 아에루기노사, 스타필로코쿠스 아우레우스, 클렙시엘라 뉴모니아 또는 클로스트리듐 테타니로부터 유래된 백신 조성물.
  26. 제24항에 있어서, 중합체 또는 올리고머는 폴리리보실리비톨 포스페이트인 백선 조성물.
  27. 제25항에 있어서, 중합체 또는 올리고머는 스트렙토코쿠스 뉴모니아로 부터 유래된 백신 조성물.
  28. 제27항에 있어서, 중합체 또는 올리고머는 에스. 뉴모니아의 혈청형 1, 4, 5, 6A, 6B, 9V, 14, 18C, 19F 또는 23F로 부터 유래된 접합체.
  29. 제25항에 있어서, 중합체 또는 올리고머는 앤. 메닝기티디스의 그룹 A 또는 그룹 C협막 망으로 부터 유래된 백신 조성물.
  30. 제18항에 있어서, 부가적으로 명반의 미네랄 현탁액을 포함하는 백신 조성물.
  31. 제약학적으로 허용가능한 담체 및 임의의 보조제내에, 수용체가 면역시스템의 세포상에서 발현되고, 면역조절활성을 갖는 시트킨, 림포킨, 호르몬, 성장인자 또는 이의 일부에 결합된 보통은, 시트킨, 림포킨, 호르몬 또는 성장인자와 또는 이의 일부에 결합된, 보통은 시토킨, 림포킨, 호르몬 또는 성장인자와 결합되지 않는 항원으로 구성되는 면역원성 접합체를 포함하는 액신 조성물의 유효량을 용현 숙주에 투여함으로 구성되는, 항원, 약한 면역원성 항원 또는 비면역원성 항원에 대하여 보호 면역반응을 유도하는 방법.
  32. 제31항에 있어서, 시트킨 또는 림포킨은 인터페론, 인터루킨 -1α, 인터루킨 -1β, 인터루킨 -2 또는 이의 일부인 액신 조성물.
  33. 제31항에 있어서, 호르몬 또는 성장인자가 종양괴사인자, 프롤락틴, 표피성장인자, 조직성장인자, 과립구 거대세포 집락 자극인자, 과립구 짐락 자극인자, 인슐린 유시 성장인자, 소마토트로핀 또는 인슐린인 백신 조성물.
  34. 제31항에 있어서, 항원은 탄수화물 함유 항원인 방법.
  35. 제약학적으로 허용가능한 담체 및 임의의 보조제내에, 수용체가 면역시스템의 세포상에서 발현되고, 면역조절활성을 갖는 시트킨, 림포킨, 호르몬, 성장인자 또는 이의 일부에 결합된, 보통은, 시트킨, 림포킨, 호르몬 또는 성장인자와 또는 이의 일부에 결합된, 보통은 시트킨, 림포킨, 호르몬 또는 성장인자와 결합되지 않는 항원으로 구성되는 면역원성 접합체와 혼합된, 항원 또는 이의 단편을 포함하는, 접합원 항원 및 적어도 하나의 다른 항원에 대해 면역반응을 유도하기위한 공동백신 조성물.
  36. 제35항에 있어서, 시포킨 또는 림포킨은 인티페론, 인터루킨 -1α 인티루킨 -1β, 인티루킨 -2 또는이의 일부인 공동 백신 조성물.
  37. 제35항에 있어서, 호르몬 또는 성장인자는 공양피사인사, 프롤락틴, 표피성장인자, 조직성장인자, 과립구 대시세포 집락 자극인자, 과립구 집락 자극인자, 인슐린 유사 성장인자, 소마도트로핀 또는 인슐린인 백신 조성물.
  38. 제35항에 있어서. 접합된 항원은 탄수화물 함유 항원인 공동 백신 조성물.
  39. 제38항에 있어서, 접합된 항원은 세균 현막 중합체, 올리고머 또는 이의 단편인 공동백신 조성물.
  40. 제39항에 있어서, 중합체 또는 올리고머는 헤모필루스 인플루옌자, 에쉐리시아 콜리, 네이세리아 메닝기티디스, 스트렙트코쿠스뉴모니아, 스트렙트코쿠스피오게네스, 브란하델라카타르할리스, 비브리오 콜레라, 코리박테리아디프테리아, 네이세리아고노르호에아, 보르데텔라 퍼투스시스, 슈도모나스 아에루기노사, 스타필로코쿠스 아우레우스, 클렙시엘라 뉴보니아 또는 클로스트리듐 테타니로부터 유래된 공동백신 조성물.
  41. 제40항에 있어서, 중합체 또는 올리고머는 클리리보실리비를 포스페이트인 공동백신 조성물.
  42. 제40항에 있어서, 중합체 또는 올리고머는 스트레비트코쿠스 뉴모니아로 부터 유래된 공동백신 조성물.
  43. 제42항에 있어서, 중합체 또는 올리고머는 에스. 뉴모니아의 혈청형 1, 4, 5, 6A, 6B, 9V, 14, 18C, 19F 또는 23F로 부터 유래된 접합체.
  44. 제40항에 있어서, 중합체 또는 올리고머는 엔. 메닝기티디스의 그룹 A 또는 그룹 C협막 당으로 부터 유래된 백신 조성물.
  45. 제35항에 있어서, 항원은 세균의 세포벽 펩티도글리칸 또는 이의 단편인 공동백신 조성물.
  46. 제35항에 있어서, 항원은 세균의 지방다당류 또는 이의 성분인 공동백신 조성물.
  47. 제35항에 있어서, 항원은 미생물 항원, 비루스 항원, 기생생물 항원, 종양 항원, 알레르겐, 호르몬, 수용체, 결합 단백질, 자가항원 및 자동면역 관련 항원으로 구성되는 군으로부터 선택된 공동백신 조성물.
  48. 제47항에 있어서, 항원은 세균 표면 또는 외막 단백질 또는 이의 일부인 공동백신 조성물.
  49. 제48항에 있어서, 항원은 헤모필루스 인플루엔자, 에쉐리시아 콜리, 네이세리아 메닝기티디스, 스트렙토코쿠스뉴모니아, 스트렙트코쿠스 피오게네스, 브란하멜라 카타르할리스, 비브리오 콜레라, 코리네박테리아 디프테리아, 네이세리아 고노르흐에아, 브르데텔라 퍼투스시스, 슈도모나스 아에루기노사, 스타필로코쿠스 아우레우스, 클렙시엘라 뉴모니아 또는 클로스트리듐 테타니의 세균외막 단백질 또는 이의 일부인 공동백신 조성물.
  50. 제48항에 있어서, 세균의 표면 단백질은 스트렙트코쿠스 피오게네스의 M단백질인 공동백신 조성물.
  51. 제47항에 있어서, 항원은 호흡 융합세포 비루스의 F, N 또는 G단백질인 공동백신 조성물.
  52. 제51항에 있어서, 항원은 호흡 융합세포 비루스 단백질 F의 펩티드 283-315인 공동백신 조성물.
  53. 제35항에 있어서, 부가적으로 명반의 미네랄 현탁액을 포함하는 공동백식 조성물.
  54. 폴리리보실리비톨포스페이트의 면역원성 활성을 조절할 수 있는 인터루킨 -2에 결합된 폴리리보실리비톨포스페이트로 구성되는 면역원성 집합체.
  55. 제약학적으로 허용가능한 담체 및 임의의 보조제내에 폴리리 보실리비롤포스페이트의 면역원성 활성을 조절할 수 있는 인더루킨 -2에 결합된 폴리리보실리비톨포스페이트로 구성되는 면역원성 접합체를 포함하는 백신조성물.
    ※ 참고사항:최초출원 내용에 의하여 공개하는 것임.
KR1019920700087A 1989-07-14 1990-07-16 접합체 백신을 위한 시토킨 및 호르몬 운반체 KR920703114A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38056689A 1989-07-14 1989-07-14
US380,566 1989-07-14
PCT/US1990/003983 WO1991001146A1 (en) 1989-07-14 1990-07-16 Cytokine and hormone carriers for conjugate vaccines

Publications (1)

Publication Number Publication Date
KR920703114A true KR920703114A (ko) 1992-12-17

Family

ID=23501660

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920700087A KR920703114A (ko) 1989-07-14 1990-07-16 접합체 백신을 위한 시토킨 및 호르몬 운반체

Country Status (8)

Country Link
US (1) US5334379A (ko)
EP (1) EP0482068A1 (ko)
JP (1) JPH04506662A (ko)
KR (1) KR920703114A (ko)
AU (1) AU651949B2 (ko)
CA (1) CA2063271A1 (ko)
FI (1) FI920131A0 (ko)
WO (1) WO1991001146A1 (ko)

Families Citing this family (203)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043057A (en) * 1988-09-16 2000-03-28 Vitec Aktiebolag Recombinant systems for expression of the cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
JP3105629B2 (ja) * 1991-04-23 2000-11-06 サングスタット メディカル コーポレイション 特異的結合ペアのメンバーの細胞活性調節接合体
IL105503A (en) * 1992-04-28 1999-05-09 Astra Ab Carbon peptide couplets capable of eliciting an immune response of T cells
CA2139756A1 (en) * 1992-07-08 1994-01-20 Eric M. Bonnem Use of gm-csf as a vaccine adjuvant
US5712118A (en) * 1993-09-29 1998-01-27 Research Foundation Of State University Of New York Vaccine for branhamella catarrhalis
US5874085A (en) * 1993-11-10 1999-02-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Vaccine for enhanced production of IgA antibodies
WO1995013089A1 (en) * 1993-11-10 1995-05-18 Henry M. Jackson Foundation For The Advancement Of Military Medicine Compositions and method for stimulating antibody release by b lymphocytes
CA2137639C (en) * 1993-12-09 1999-01-26 Agustin B. L. Davila Vaccine composition comprising autologous epidermal growth factor or a fragment or a derivate thereof having anti-tumor activity and use thereof in the therapy of malignant diseases
CA2261433A1 (en) * 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
JPH09506866A (ja) * 1993-12-14 1997-07-08 ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 医薬として活性のある物質の免疫療法のための放出制御
US5674483A (en) * 1995-01-31 1997-10-07 National Jewish Medical And Research Center Treatment for diseases involving inflammation
CA2227013A1 (en) 1995-07-14 1997-02-06 Glycotech Corp. Compounds and methods for treatment of egf receptor associated cancers and purification of the egf receptor
US6080409A (en) * 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
DE69726674T2 (de) * 1996-04-10 2004-10-21 Sangstat Medical Corp Zellmodulierende konjugate aus elementen aus spezifischen bindungspaaren
US6685949B1 (en) 1998-01-13 2004-02-03 The United States Of America As Represented By The Department Of Health & Human Services Lipooligosaccharide based vaccine for prevention of moraxella (branhamella)catarrhalis infections in humans
US6716433B1 (en) * 1997-09-12 2004-04-06 University Of Tennessee Research Foundation Group a streptococcal vaccines
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
CA2310252A1 (en) * 1998-03-06 1999-09-10 Imclone Systems Incorporated Active immunization against angiogenesis-associated antigens
US6506385B1 (en) 1998-04-17 2003-01-14 Embrex, Inc. Live vaccines and methods of treatment therewith
US6921811B2 (en) * 1998-09-22 2005-07-26 Biosurface Engineering Technologies, Inc. Bioactive coating composition and methods
US6342591B1 (en) 1998-09-22 2002-01-29 Biosurface Engineering Technologies, Inc. Amphipathic coating for modulating cellular adhesion composition and methods
US6596699B2 (en) 1998-09-22 2003-07-22 Biosurface Engineering Technologies, Inc. Nucleic acid coating compositions and methods
US6270758B1 (en) 1998-10-08 2001-08-07 Duke University Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
DE69901377T2 (de) * 1999-01-27 2003-01-02 Idea Ag Nichtinvasive Impfung durch die Haut
ATE413191T1 (de) * 1999-12-03 2008-11-15 Celltech Chiroscience Ltd Verwendung of interleukin-1 mutein als impfstoffadjuvans
AU784557B2 (en) * 1999-12-21 2006-05-04 Merial Compositions and vaccines containing antigen(s) of cryptosporidium parvum and of another pathogen
HUP0300421A2 (hu) 2000-03-31 2003-06-28 Purdue Research Foundation Kezelési eljárás ligand-immunogén konjugátumok felhasználásával
US6911204B2 (en) * 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
EP1309373A2 (en) * 2000-08-11 2003-05-14 Favrille, Inc. Method and composition for altering a t cell mediated pathology
US7527797B1 (en) * 2000-09-01 2009-05-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Vibrio cholerae 0139 conjugate vaccines
CA2427572A1 (en) * 2000-11-01 2002-05-10 The Regents Of The University Of California Immunomodulatory peptides derived from heat shock proteins and uses thereof
CU23077A1 (es) * 2000-12-06 2005-08-17 Centro Inmunologia Molecular Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
CU22999A1 (es) 2001-12-04 2004-10-12 Centro Inmunologia Molecular Método de tratamiento de enfermedades malignas e infecciosas crónicas
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
AU2002365223A1 (en) * 2001-10-26 2003-09-02 Id Biomedical Corporation Of Washington Multivalent streptococcal vaccine compositions and methods for use
MXPA04011249A (es) 2002-05-14 2005-06-06 Chiron Srl Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
FR2844514B1 (fr) 2002-09-16 2007-10-19 Neovacs Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation
CA2501812C (en) 2002-10-11 2012-07-10 Mariagrazia Pizza Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
ATE466875T1 (de) 2002-11-15 2010-05-15 Novartis Vaccines & Diagnostic Unerwartete oberflächenproteine in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
ES2411080T3 (es) 2003-01-30 2013-07-04 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
EP1668112A4 (en) 2003-06-20 2009-04-29 Protein Sciences Corp SARS IMMUNOGENOUS EXPRESSING VECTORS, SUCH VECTORS OR EXPRESSION PRODUCTS COMPRISING THOSE COMPOSITIONS, PROCESSES AND TESTS FOR THE PREPARATION AND USE THEREOF
RU2378010C2 (ru) 2003-10-02 2010-01-10 Новартис Вэксинес Энд Дайэгностикс С.Р.Л. Жидкие вакцины для множественных серогрупп менингококков
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
US20090317420A1 (en) 2004-07-29 2009-12-24 Chiron Corporation Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
HUE027400T2 (en) 2005-02-18 2016-10-28 Glaxosmithkline Biologicals Sa Proteins and nucleic acids from meningitis / sepsis with Escherichia coli
ES2385045T3 (es) 2005-02-18 2012-07-17 Novartis Vaccines And Diagnostics, Inc. Inmunógenos de Escherichia coli uropatogénica
WO2006113528A2 (en) 2005-04-18 2006-10-26 Novartis Vaccines And Diagnostics Inc. Expressing hepatitis b virus surface antigen for vaccine preparation
WO2007022813A2 (en) 2005-05-24 2007-03-01 Neovacs A METHOD FOR PREPARING A STABLE IMMUNOGENIC PRODUCT COMPRISING ANTIGENIC HETEROCOMPLEXES OF TNFα AND A CARRIER PROTEIN
PT2351578T (pt) 2005-06-27 2017-04-07 Glaxosmithkline Biologicals Sa Processo para o fabrico de vacinas
EP2308505A3 (en) 2005-09-01 2011-11-30 Novartis Vaccines and Diagnostics GmbH Multiple vaccines including serogroup C meningococcus
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
EP2360175B1 (en) 2005-11-22 2014-07-16 Novartis Vaccines and Diagnostics, Inc. Norovirus and Sapovirus virus-like particles (VLPs)
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
LT3017827T (lt) 2005-12-22 2019-01-10 Glaxosmithkline Biologicals S.A. Pneumokokinė polisacharidinė konjuguota vakcina
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
SI2004225T1 (sl) 2006-03-22 2012-08-31 Novartis Ag Reĺ˝imi za imunizacijo z meningokoknimi konjugati
US20110206692A1 (en) 2006-06-09 2011-08-25 Novartis Ag Conformers of bacterial adhesins
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
MX2009002560A (es) 2006-09-07 2009-03-20 Glaxosmithkline Biolog Sa Vacuna.
US20080118524A1 (en) * 2006-10-20 2008-05-22 Stefan Persson Anti-IgE Vaccines
WO2008130382A2 (en) * 2006-10-31 2008-10-30 East Carolina University Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
EA201490303A1 (ru) 2007-05-02 2014-05-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
KR20100045445A (ko) 2007-06-26 2010-05-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 스트렙토코쿠스 뉴모니애 캡슐 다당류 컨쥬게이트를 포함하는 백신
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
RU2471497C2 (ru) 2007-09-12 2013-01-10 Новартис Аг Мутантные антигены gas57 и антитела против gas57
CA2702871A1 (en) 2007-10-19 2009-04-23 Novartis Ag Meningococcal vaccine formulations
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
CN104292312A (zh) 2007-12-21 2015-01-21 诺华股份有限公司 链球菌溶血素o的突变形式
EP2245048B1 (en) 2008-02-21 2014-12-31 Novartis AG Meningococcal fhbp polypeptides
HUE029265T2 (en) 2008-10-27 2017-02-28 Glaxosmithkline Biologicals Sa Method of purifying carbohydrates from the group streptococci
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
CN102300585A (zh) 2008-12-17 2011-12-28 诺华有限公司 包含血红蛋白受体的脑膜炎球菌疫苗
MX2011007456A (es) 2009-01-12 2011-08-03 Novartis Ag Antigenos del dominio de proteina de superficie de union a colageno tipo b (can_b) en vacunas contra bacteria gram positiva.
WO2010109323A1 (en) 2009-03-24 2010-09-30 Novartis Ag Adjuvanting meningococcal factor h binding protein
WO2010109324A1 (en) 2009-03-24 2010-09-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
CA2757287C (en) 2009-03-31 2019-09-10 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
SG175092A1 (en) 2009-04-14 2011-11-28 Novartis Ag Compositions for immunising against staphylococcus aerus
BRPI1014494A2 (pt) 2009-04-30 2016-08-02 Coley Pharm Group Inc vacina pneumocócica e usos da mesma
WO2010132833A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
AU2010288240B2 (en) 2009-08-27 2014-03-27 Novartis Ag Hybrid polypeptides including meningococcal fHBP sequences
PE20161560A1 (es) 2009-09-03 2017-01-11 Pfizer Vaccines Llc Vacuna de pcsk9
US20120237536A1 (en) 2009-09-10 2012-09-20 Novartis Combination vaccines against respiratory tract diseases
WO2011039631A2 (en) 2009-09-30 2011-04-07 Novartis Ag Expression of meningococcal fhbp polypeptides
JP2013506651A (ja) 2009-09-30 2013-02-28 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ．ａｕｒｅｕｓ５型および８型莢膜多糖の結合体
AU2010310985B2 (en) 2009-10-27 2014-11-06 Glaxosmithkline Biologicals S.A. Modified meningococcal fHBP polypeptides
PT2493498T (pt) 2009-10-30 2017-05-24 Glaxosmithkline Biologicals Sa Purificação de sacáridos capsulares de staphylococcus aureus tipo 5 e tipo 8
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
EP2585106A1 (en) 2010-06-25 2013-05-01 Novartis AG Combinations of meningococcal factor h binding proteins
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
CA2860331A1 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
US10286056B2 (en) 2011-01-27 2019-05-14 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with crystallisation inhibitors
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
EP2688590B1 (en) 2011-03-24 2020-02-12 GlaxoSmithKline Biologicals SA Adjuvant nanoemulsions with phospholipids
WO2013009564A1 (en) 2011-07-08 2013-01-17 Novartis Ag Tyrosine ligation process
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
CN103917245B (zh) 2011-09-14 2017-06-06 葛兰素史密丝克莱恩生物有限公司 用于制备糖‑蛋白质糖缀合物的方法
CA2854934A1 (en) 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
RU2014127714A (ru) 2011-12-08 2016-01-27 Новартис Аг ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
JP2015505309A (ja) 2011-12-29 2015-02-19 ノバルティス アーゲー 髄膜炎菌ｈ因子結合タンパク質のアジュバントされた組み合わせ
CN104321335A (zh) 2012-02-24 2015-01-28 诺华股份有限公司 菌毛蛋白质和组合物
EP2822586A1 (en) 2012-03-07 2015-01-14 Novartis AG Adjuvanted formulations of streptococcus pneumoniae antigens
JP2015509963A (ja) 2012-03-08 2015-04-02 ノバルティス アーゲー Ｔｌｒ４アゴニストを含む混合ワクチン
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA2871520C (en) 2012-04-26 2020-12-29 Novartis Ag Antigens from non-typeable h. influenzae
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
SG11201407440WA (en) 2012-05-22 2014-12-30 Novartis Ag Meningococcus serogroup x conjugate
JP6324961B2 (ja) 2012-09-06 2018-05-16 ノバルティス アーゲー 血清群ｂ髄膜炎菌とｄ／ｔ／ｐとの組み合わせワクチン
SG11201500979RA (en) 2012-10-03 2015-07-30 Glaxosmithkline Biolog Sa Immunogenic composition
EP3620172A1 (en) 2012-10-12 2020-03-11 GlaxoSmithKline Biologicals SA Non-cross-linked acellular pertussis antigens for use in combination vaccines
US9987344B2 (en) 2012-11-30 2018-06-05 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations
EP2950819B1 (en) 2013-02-01 2018-03-28 GlaxoSmithKline Biologicals SA Intradermal delivery of immunological compositions comprising toll-like receptor agonists
EP3041502A2 (en) 2013-09-08 2016-07-13 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
EP3583947B1 (en) 2014-01-21 2023-10-11 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
ES2883343T3 (es) 2014-01-21 2021-12-07 Pfizer Polisacáridos capsulares de Streptococcus pneumoniae y conjugados de los mismos
EP3096785B1 (en) 2014-01-21 2020-09-09 Pfizer Inc Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US10668164B2 (en) 2014-02-14 2020-06-02 Pfizer Inc. Immunogenic glycoprotein conjugates
CA2940447C (en) 2014-02-28 2023-07-11 Glaxosmithkline Biologicals Sa Modified meningococcal fhbp polypeptides
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3034516A1 (en) 2014-12-19 2016-06-22 Novartis AG Purification of streptococcal capsular polysaccharide
DK3244917T5 (da) 2015-01-15 2024-10-14 Pfizer Inc Immunogene sammensætninger til anvendelse i pneumokokvacciner
PE20180657A1 (es) 2015-07-21 2018-04-17 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
CA3005524C (en) 2015-11-20 2023-10-10 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CR20180350A (es) 2015-12-04 2018-10-02 Dana Farber Cancer Inst Inc Vacunación con el dominio alfa 3 de mica/b para el tratamiento del cáncer
WO2017175082A1 (en) 2016-04-05 2017-10-12 Gsk Vaccines S.R.L. Immunogenic compositions
US12109259B2 (en) 2016-09-02 2024-10-08 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
WO2018104889A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Biologicals Sa Purification process for capsular polysaccharide
SI3570879T1 (sl) 2017-01-20 2022-06-30 Pfizer Inc. Imunogenska kompozicija za uporabo v pnevmokoknih cepivih
IL267733B2 (en) 2017-01-31 2023-10-01 Pfizer NEISSERIA MENINGITIDIS preparations and methods therefor
KR102650073B1 (ko) 2017-01-31 2024-03-20 머크 샤프 앤드 돔 엘엘씨 스트렙토코커스 뉴모니아 혈청형 19f 유래의 협막 다당류 단백질 접합체의 제조 방법
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
DK3678654T3 (da) 2017-09-07 2024-09-02 Merck Sharp & Dohme Llc Pneumokokpolysaccharider og anvendelse deraf i immunogene polysaccharid-bærerprotein-konjugater
TWI725359B (zh) 2017-12-06 2021-04-21 美商默沙東藥廠 包含肺炎鏈球菌多醣-蛋白結合物之組合物及其使用方法
WO2020016322A1 (en) 2018-07-19 2020-01-23 Glaxosmithkline Biologicals Sa Processes for preparing dried polysaccharides
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
JP2022512345A (ja) 2018-12-12 2022-02-03 ファイザー・インク 免疫原性多重ヘテロ抗原多糖－タンパク質コンジュゲートおよびその使用
JOP20210148A1 (ar) 2018-12-19 2023-01-30 Merck Sharp & Dohme تركيبات تشتمل على متقارنات بولي سكاريد-بروتين للمكورات العقدية الرئوية وطرق استخدامها
EP3923982A1 (en) 2019-02-11 2021-12-22 Pfizer Inc. Neisseria meningitidiscompositions and methods thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
CN113966234A (zh) 2019-05-10 2022-01-21 葛兰素史克生物有限公司 缀合物的产生
MX2022001241A (es) 2019-07-31 2022-04-20 Sanofi Pasteur Inc Composiciones de conjugados neumococicos multivalentes polisacarido - proteina y metodos para usar los mismos.
EP4034157A1 (en) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
IL292494A (en) 2019-11-01 2022-06-01 Pfizer Preparations of Escherichia coli and their methods
CN114728051A (zh) 2019-11-22 2022-07-08 葛兰素史克生物有限公司 细菌糖糖缀合物疫苗的剂量和施用
WO2021165847A1 (en) 2020-02-21 2021-08-26 Pfizer Inc. Purification of saccharides
EP4107170A2 (en) 2020-02-23 2022-12-28 Pfizer Inc. Escherichia coli compositions and methods thereof
EP4165064A2 (en) 2020-06-12 2023-04-19 GlaxoSmithKline Biologicals S.A. Dock tag system
GB202013262D0 (en) 2020-08-25 2020-10-07 Glaxosmithkline Biologicals Sa Vaccine Composition
JP2023546446A (ja) 2020-10-22 2023-11-02 ファイザー・インク 細菌多糖を精製する方法
IL302362A (en) 2020-10-27 2023-06-01 Pfizer ESCHERICHIA COLI preparations and their methods
CN116744965A (zh) 2020-11-04 2023-09-12 辉瑞大药厂 用于肺炎球菌疫苗的免疫原性组合物
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
TW202245835A (zh) 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
CA3218544A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
JP2024522395A (ja) 2021-05-28 2024-06-19 ファイザー・インク コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
US20220387576A1 (en) 2021-05-28 2022-12-08 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2023207315A1 (en) 2022-01-13 2024-06-27 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2023218322A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
US20240181028A1 (en) 2022-11-22 2024-06-06 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
AU573529B2 (en) * 1982-05-12 1988-06-16 President And Fellows Of Harvard College Hybrid proteins
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
GB8315980D0 (en) * 1983-06-10 1983-07-13 Biogen Nv Producing hybrid dna sequences
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4987237A (en) * 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
EP0158198A1 (en) * 1984-03-29 1985-10-16 Takeda Chemical Industries, Ltd. DNA and use thereof
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
EP0229108B1 (en) * 1985-06-26 1990-12-27 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4772685A (en) * 1985-10-02 1988-09-20 Merck & Co., Inc. Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
US5013824A (en) * 1985-11-19 1991-05-07 Schering Corporation Human interleukin-4 peptides and conjugates thereof
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4962188A (en) * 1985-12-06 1990-10-09 Cetus Corporation Recombinant ricin toxin A chain conjugates
US4820514A (en) * 1985-12-30 1989-04-11 Texas A&M University System Low dosage of interferon to enhance vaccine efficiency
US4745180A (en) * 1986-06-27 1988-05-17 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using heparin fragments
US4902505A (en) * 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4801575A (en) * 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
AU612983B2 (en) * 1986-08-01 1991-07-25 Australian National University, The Recombinant vaccine
US4879374A (en) * 1987-03-13 1989-11-07 Immunex Corporation Bovine interleukin-1β DNA sequence
US4946945A (en) * 1987-06-23 1990-08-07 Allergy Immuno Technologies, Inc. Immunotherapy agents for treatment of IgE mediated allergies
DE68924850T2 (de) * 1988-06-14 1996-10-10 Cell Med Inc Heterofunktionelle zellular immunologische reagenzien, impfstoffe daraus und verwendungsverfahren.
US5039790A (en) * 1989-01-11 1991-08-13 Monsanto Company Bioactive fragment of interleukin-1-B that has antagonistic activity
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3

Also Published As

Publication number Publication date
AU6055090A (en) 1991-02-22
CA2063271A1 (en) 1991-01-15
US5334379A (en) 1994-08-02
EP0482068A1 (en) 1992-04-29
FI920131A0 (fi) 1992-01-13
WO1991001146A1 (en) 1991-02-07
AU651949B2 (en) 1994-08-11
JPH04506662A (ja) 1992-11-19

Similar Documents

Publication Publication Date Title
KR920703114A (ko) 접합체 백신을 위한 시토킨 및 호르몬 운반체
DK171420B1 (da) Kovalent-modificeret bakterielt polysaccharid/protein-konjugat, fremgangsmåde til fremstilling deraf og præparat omfattende et polysaccharid/protein-konjugat
JP6950099B2 (ja) 多価肺炎球菌多糖体−タンパク質複合体組成物
Alexander et al. Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses
AU676497B2 (en) Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
US5955079A (en) Dual carrier immunogenic construct
AU678613B2 (en) Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
EP0471177B1 (en) Filamentous hemagglutinin of bordetella pertussis as a carrier molecule for conjugate vaccines
AU2005316864B2 (en) Glycoconjugate vaccines containing peptidoglycan
KR920703103A (ko) 인터루킨을 함유하는 안정한 백신 조성물
GR3035081T3 (en) Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
WO2007113224A2 (en) Conjugation process for pnag and a carrier protein
NO300759B1 (no) Fremgangsmåte for fremstilling av et kovalent konjugat av et oligosakkarid og et bærerprotein
KR20100044265A (ko) 면역약화된 집단에 사용하기 위한 당결합체 백신
Fattom et al. Effect of conjugation methodology, carrier protein, and adjuvants on the immune response to Staphylococcus aureus capsular polysaccharides
NZ309713A (en) Oligosaccharides of S pneumoniae serotype 8 and their use in a vaccine
Coughlin et al. Adjuvant activity of QS-21 for experimental E. coli 018 polysaccharide vaccines
JP2000507252A (ja) 免疫性物質を産生する方法及びワクチン
TW202233659A (zh) 重組多肽，包含該重組多肽的複合物，以及其用途
CN108743936B (zh) 一种细菌多糖结合疫苗及其制备方法与应用
Wei et al. The phenyl linker markedly increases the immunogenicity of the pneumococcal polysaccharide conjugate vaccine
Messner et al. Vaccine development based on S-layer technology
Fattom Qualitative and quantitative immune response to bacterial capsular polysaccharides and their conjugates in mouse and man
JP2660511B2 (ja) 経口ワクチン
Pozsgay Bacterial polysaccharide-protein conjugate

Legal Events

Date Code Title Description
A201 Request for examination
N231 Notification of change of applicant
E902 Notification of reason for refusal
E601 Decision to refuse application